Abstract
Objective: Examine survival and risk factor effects in a cohort of cognitive impairment not dementia (CIND) and dementia. Compare survival to general population in British Columbia (BC). Background: Estimates of survival are integral to the care of patients diagnosed with dementia. Few Canadian studies have long-term follow-up of well-described cohorts, analyzing survival with multiple risk factors. Design/Methods: We studied survival at a single ACCORD center site. 218 patients diagnosed with CIND or dementia followed from recruitment between 1997-1999. Vital status completed for all patients on censor date (June 20, 2015). Risk factors including age, sex, education, MMSE, CIRS, NPI, FRS, DAD, Hachinski, vascular risk factors, APOE4, and AchEI use evaluated in AD and Other Dementias (OD) subgroups using Kaplan-Meier and Cox regression. Survival compared to age-matched life expectancy in BC. Results: Overall 183 (84[percnt]) deaths observed over 16.6 years mean follow up. 16/39 (41[percnt]) CIND died; 136/144 (94[percnt]) AD died; 31/35 (89[percnt]) OD died (median survival for dementia groups: 7.1 years). Given the heterogeneity and small sample size of CIND, effects of risk factors were evaluated only in patients with dementia. Survival times did not vary between AD and OD (p=0.53). Shorter survival was associated with age, DAD scores <55[percnt] (HR 1.92, 95[percnt]CI 1.20-3.08) and CIRS scores >7 (HR 1.90, 95[percnt]CI 1.23-2.93); the latter two remained significant after adjustment. No significant effect was observed with other variables. Compared to BC population, decrease of life expectancy for dementia subjects aged 65-69 was 11.35 years and 1.82 years for ≥80. Conclusions: Survival with dementia is shorter than population life expectancies for each age strata, with greatest impact in younger patients. Cumulative medical illness and functional disabilities are the most significant predictors of survival and can guide prognosis. ACCORD funded by Canada’s Medical Research Council (now CIHR) and Pharmaceutical Manufacturers’ Association of Canada.
Disclosure: Dr. Lichtenstein has nothing to disclose. Dr. Fallah has received personal compensation in an editorial capacity for HSOA Journal of Gerontology & Geriatric Medicine. Dr. Feldman has received personal compensation for activities with Merck, Eli Lilly and Arena and Eisai and Genentech Banne as a member of safety and diagnostic monitoring committees.
Saturday, April 16 2016, 8:30 am-7:00 pm
- Copyright © 2016 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.